Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Manufacturer Direct-to-Patient (Cash-Pay) Programs Both Novo Nordisk and Eli Lilly have launched direct-to-patient platforms offering GLP-1 medications at flat cash-pay rates significantly below the insurance list price
Semaglutide helps regulate your appetite, making it easier to feel full and stay in control of your food choices
In May 2026, Lilly announced phase 3 TRIUMPH-1 results reporting mean weight reductions of up to 28.3% at 80 weeks in the highest retatrutide study group
The platform delivers the content for you from a plan thats already set it and forget it
US$ 22.37
US$ 20.33
US$ 26.61
US$ 26.67
US$ 23.04
US$ 25.70
